fulzerasib

AXP000031.1 · Targeted small molecule

Platform
small molecule
Targets
KRAS
Originator
GenFleet Therapeutics
Sponsor
Innovent Biologics (Greater China); GenFleet Therapeutics (ex-China)

Names

NameTypeSource
fulzerasibpreferred name, INNcurator, ncit
Dupertbrandpress
GFH925codencit
IBI351codencit

Cross-references

NCI Thesaurus
C199055
FDA UNII
6D5B7F245W

Approvals

No regulatory approval recorded.

Clinical trials (14)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT07601048A Trial of HRS-7058 in Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard TreatmentNot yet recruitingPhase 32026-062028-05450KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard Treatment
NCT07581912Neoadjuvant Treatment of Fulzerasib Plus Cetuximab N01 in KRAS G12C Mutated Locally Advanced Colorectal Cancer With or Without Resectable MetastasesRecruitingPhase 22026-04-302028-1240Cetuximab N01; Colorectal Cancer; Fulzerasib; KRAS G12C Mutant Advanced Solid Tumors
NCT07463677Tunlametinib Combination Therapy in KRAS-Mutated Unresectable Locally Advanced or Metastatic Non-Small Cell Lung CancerNot yet recruitingPhase 22026-03-152028-05-3155Lung Cancer (NSCLC)
NCT07492342Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLCRecruitingPhase 22026-01-292027-03-3130KRAS G12C Mutation; Neoadjuvant Therapy; Resectable NSCLC; Stage IB-IIIA NSCLC
NCT07198841IBI351 Plus Cetuximab β in Untreated Advanced Non-small Cell Lung Cancer With KRAS G12C MutationRecruitingPhase 22025-11-032027-0948Lung Cancer (Non-Small Cell)
NCT06959589The Efficacy and Safety of IBI351, Cetuximab β Combined With FOLFIRI as First-line /IBI351, Cetuximab β as Second-line in the Treatment of KRAS G12C-mutated Metastatic Colorectal CancerEnrolling by invitationPhase 22025-05-222027-05-3150Colorectal Cancer Metastatic; KRAS G12C Mutation
NCT06936644A Multicenter, Single-arm Phase II Study to Evaluate the Efficacy and Safety of Fulzerasib (IBI351) in Combination With Ivonescimab (AK-112) in First-line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer Patients With KRAS G12C MutationNot yet recruitingPhase 22025-04-302027-04-3039KRAS G12C Lung Cancer
NCT05756153A Study of GFH925 in Combination With Cetuximab in Previously Untreated Advanced NSCLC Harboring KRAS G12C MutationCompletedPhase 1/22023-04-252025-04-3047Advance Non-small Cell Lung Cancer
NCT05699993A Study of IBI351 in Healthy SubjectsCompletedPhase 12023-03-102023-10-1624Healthy Subjects
NCT05626179A Study of [14C]IBI351 in Healthy SubjectsCompletedPhase 12023-02-182023-03-306Healthy Subjects
NCT05688124A Study of IBI351 in Healthy SubjectsCompletedPhase 12023-02-162023-10-1624Healthy Subjects
NCT05504278Efficacy and Safety of IBI351 in Combination With Chemotherapy in Advanced Non-squamous Non-small Cell Lung Cancer Subjects With KRAS G12C MutationRecruitingPhase 12022-09-202025-05-31144Advanced Non-Small Cell Lung Cancer
NCT05497336A Study of IBI351 in Combination With Cetuximab in Subjects With KRAS G12C Mutated Metastatic Colorectal CancerTerminatedPhase 12022-08-182025-01-248Colorectal Cancer
NCT05005234A Study of GFH925 in Patients With Advanced Solid Tumors With KRAS G12C MutationsCompletedPhase 1/22021-09-132023-02-20334KRAS G12C
Unconfirmed matches (1)

Trials that mention one of the names in a weaker way (a code only in the title, a short or ambiguous name). Not counted above.

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditionsMatched by
NCT07198620A Real-World Study of IBI351 for KRAS G12C+ NSCLC in ChinaNot yet recruiting2025-10-012026-06-01600Lung Cancer (NSCLC)name in title: IBI351

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 41926959Fulzerasib plus cetuximab in first-line KRASG12C-mutated non-small-cell lung cancer (KROCUS): a single-arm, multicentre, phase 1b/2 trial.The Lancet. Oncology2026cited by trial NCT05756153
PMID 40715048Efficacy and safety of IBI351 (fulzerasib) monotherapy in KRASG12C inhibitor-naïve Chinese patients with KRASG12C-mutated metastatic colorectal cancer: a pooled analysis from phase I part of two studies.Signal transduction and targeted therapy2025cited by trial NCT05005234
PMID 39127176Efficacy and Safety of KRASG12C Inhibitor IBI351 Monotherapy in Patients With Advanced NSCLC: Results From a Phase 2 Pivotal Study.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer2024cited by trial NCT05005234
PMID 39357276Potent covalent irreversible inhibitor of KRAS G12C IBI351 in patients with advanced solid tumors: First-in-human phase I study.European journal of cancer (Oxford, England : 1990)2024name in title: IBI351

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 41786688Cetuximab co-treatment with KRAS G12C inhibitors fulzerasib and sotorasib in human KRAS G12C non-small cell lung cancer cells.Cell death discovery2026name in title: fulzerasib
PMID 41998662MXD4 enhances resistance to KRAS G12C-targeted therapy in lung adenocarcinoma by suppressing ACSL4-mediated ferroptosis.Respiratory research2026name in abstract: fulzerasib
PMID 42448637Development and Validation of a Sensitive UHPLC-MS/MS Analytical Method for Fulzerasib in Rat Plasma and its Application to Pharmacokinetics Studies.Biomedical chromatography : BMC2026name in title: fulzerasib
PMID 42622884KRAS-Targeted Therapies in NSCLC: Resistance, Combination Strategies, and Emerging Clinical Paradigms.Medical oncology (Northwood, London, England)2026name in abstract: IBI351
PMID 42990959MRAS, SHOC2, PP1C and YAP1 mRNA level variations at 72 hours of targeted therapy in KRAS G12C-mutant non-small cell lung cancer cell lines.Annals of translational medicine2026name in abstract: fulzerasib
PMID 43001251From "undruggable" to tractable: Therapeutic advances targeting Kristen rat sarcoma viral homolog glycine to cysteine mutation at codon 12 (KRAS G12C)-mutant cancers and emerging resistance mechanisms.Cancer pathogenesis and therapy2026name in abstract: fulzerasib
PMID 39794111Revolutionizing NSCLC Treatment: Unleashing the Potential of IBI351 and Its Critical Care Impact.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer2025name in title: IBI351
PMID 39794112Letter Regarding "Revolutionizing NSCLC Treatment: Unleashing the Potential of IBI351 and Its Critical Care Impact".Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer2025name in title: IBI351
PMID 39820841Correction: Fulzerasib: First Approval.Drugs2025name in title: fulzerasib
PMID 40381703An overview of PROTACs targeting KRAS and SOS1 as antitumor agents.Bioorganic & medicinal chemistry letters2025name in abstract: fulzerasib
PMID 40701936Discovery of Fulzerasib (GFH925) for the Treatment of KRAS G12C-Mutated Solid Tumors.Journal of medicinal chemistry2025name in title: fulzerasib
PMID 40799453Literature review of advances and challenges in KRAS G12C mutant non-small cell lung cancer.Translational lung cancer research2025name in abstract: IBI351
PMID 41158041[Advances in Diagnosis and Targeted Therapy of KRASG12C Mutant Non-small Cell Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer2025name in abstract: fulzerasib
PMID 39433508Study of the mass balance, biotransformation, and safety of [ 14C]IBI351 in healthy Chinese subjects.Journal of biomedical research2024name in title: IBI351
PMID 39587006Fulzerasib: First Approval.Drugs2024name in title: fulzerasib
PMID 25945295Arthroplasty for fifth carpometacarpal joint arthritis.Journal of wrist surgery2015name in abstract: Dupert

Notes

KRAS G12C. GenFleet code GFH925; Innovent code IBI351 after Sept 2021 China licence. Approved China Aug 2024 as Dupert. Wikidata QID not confirmed.

How to cite

fulzerasib (AXP000031.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000031.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.